VEEV · NYQ · Healthcare
Veeva Systems Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 106.05
Market price
USD 260.21
Implied upside
-59.2%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Current EV/EBITDA of 37.4x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY27 | FY28 | FY29 | FY30 | FY31 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 3.6bn | USD 4.2bn | USD 4.7bn | USD 5.4bn | USD 6.2bn | +14.0% |
| EBIT | USD 850.0m | USD 969.3m | USD 1.1bn | USD 1.3bn | USD 1.4bn | +14.0% |
| NOPAT | USD 710.1m | USD 809.7m | USD 923.4m | USD 1.1bn | USD 1.2bn | +14.0% |
| Add depreciation & amortisation | USD 48.8m | USD 55.6m | USD 63.4m | USD 72.3m | USD 82.5m | +14.0% |
| Less capital expenditure | USD -48.8m | USD -55.6m | USD -63.4m | USD -72.3m | USD -82.5m | +14.0% |
| Less increase in working capital | USD 8.9m | USD 10.2m | USD 11.6m | USD 13.2m | USD 15.1m | -14.0% |
| Free cashflow to firm | USD 719.0m | USD 819.9m | USD 935.0m | USD 1.1bn | USD 1.2bn | +14.0% |
| Discount factor | 0.9518 | 0.8622 | 0.7810 | 0.7075 | 0.6409 | - |
| Present value | USD 684.4m | USD 706.9m | USD 730.2m | USD 754.3m | USD 779.1m | +3.3% |
| Present Value Of The Forecast | USD 3.7bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.983 | Reported 0.974, pulled toward 1.0 (Blume) |
| Cost of equity | 10.40% | Risk-free + beta x equity risk premium |
| Cost of debt | 7.00% | Assumed: risk-free + 2bp (interest expense not reported) |
| Market capitalisation | USD 42.1bn | 99.8% of capital |
| Total debt | USD 95.9m | 0.2% of capital, book value as a proxy |
| Tax rate | 16.5% | Effective, capped at statutory |
| WACC | 10.39% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
67% of EV
- Forecast FCFF, final year
- USD 1.2bn
- Capex at depreciation, working capital in reinvestment
- USD 1.2bn
- Less reinvestment at g/ROIC (24.1% of NOPAT)
- USD -288.8m
- Capitalised
- USD 911.8m
- ROIC (WACC floor)
- 10.4%
- Terminal value, undiscounted
- USD 11.8bn
- Terminal value, discounted
- USD 7.6bn
- Enterprise value
- USD 11.2bn
- Less net debt
- USD -6.5bn
- Equity value
- USD 17.7bn
Exit at 20.0x EBITDA
84% of EV
- Terminal value, undiscounted
- USD 30.4bn
- Terminal value, discounted
- USD 19.5bn
- Enterprise value
- USD 23.1bn
- Less net debt
- USD -6.5bn
- Equity value
- USD 29.6bn
Spread between methods: 50%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 8.39% | 124.41 | 125.70 | 127.17 | 128.87 | 130.87 |
| 9.39% | 113.70 | 114.26 | 114.86 | 115.52 | 116.26 |
| 10.39% | 105.60 | 105.83 | 106.05 | 106.27 | 106.49 |
| 11.39% | 99.52 | 99.72 | 99.91 | 100.11 | 100.30 |
| 12.39% | 94.43 | 94.60 | 94.78 | 94.95 | 95.12 |
Outlined: this model. Green text: above today's price of 260.21. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 14.0% | 48.1% | +34.1pp |
| EBIT margin | 23.3% | 77.0% | +53.6pp |
| Discount rate | 10.4% | 4.8% | -5.6pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.